IPG11406

· Nanjing Immunophage Biotech Co., Ltd

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for IPG11406, covering 2026-01-13 to 2026-04-17. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2) [Phase 2]